Clinical Trial Update: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating atezolizumab with rechallenge chemotherapy in relapsed extensive-stage small cell lung cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Status: RECRUITING